Get your free email accountLog in
U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British ...
Myriad Genetics, Inc. news and stories
Copyright 2015 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Copyright © 2015 1&1 Mail & Media Inc. All rights reserved.